Remove 2040 Remove Conditions Remove Data
article thumbnail

Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2022 Financial Results and Provides a Business Update

Cannabis Law Report

” The patent provides protection through 2040 and describes use of the Company’s investigational drug ANEB-001 to treat acute cannabinoid overdose. We recently announced a key milestone with the issuance of a method of use patent for ANEB-001, providing protection through 2040. Condensed Balance Sheet Data. . .

article thumbnail

MyMD Pharmaceuticals President Chris Chapman, M.D. Named Medical Honoree of the Year by the Arthritis Foundation

Cannabis Law Report

Studies estimate that the number of people suffering from rheumatoid arthritis may rise to over 78 million by 2040. 1 Data published by Research and Markets, March 2018. The rising prevalence of rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease are driving demand for TNF inhibitors like MYMD-1. 646) 421-9523.